Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2027

Conditions
Locally Advanced Gastric Cancer
Interventions
DRUG

Camrelizumab

Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.

DRUG

Oxaliplatin

Oxaliplatin for Injection 135mg/m2 /per day,ivgtt,in day1. Given once every 3 weeks.

DRUG

S1

S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

DRUG

Apatinib Mesylate

Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.

DRUG

Nab paclitaxel

nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.

Trial Locations (1)

350001

Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT05524974 - Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | Biotech Hunter | Biotech Hunter